ISPH 5.70 Inspire Announces Date for Conference Call and Webcast to Discuss Second Quarter 2007 Financial Results
Jul 25, 2007 7:30:00 AM
Copyright Business Wire 2007
DURHAM, N.C.--(BUSINESS WIRE)--
Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that it plans to report second quarter 2007 financial results on Wednesday, August 8, 2007 before the market opens. Inspire's President and CEO, Christy L. Shaffer, Ph.D., and CFO and Treasurer, Thomas R. Staab, II, will host a conference call and live webcast on Wednesday, August 8, 2007 at 10:00 a.m. ET.
To access the conference call, U.S. participants may call (877) 648-7970 and international participants may call (706) 902-0415. The conference ID number is 10936761. A live webcast and replay of the call will be available on Inspire's website at www.inspirepharm.com. A telephone replay of the conference call will be available until August 22, 2007. To access this replay, U.S. participants may call (800) 642-1687 and international participants may call (706) 645-9291. The conference ID number is 10936761.
About Inspire
Inspire is a biopharmaceutical company dedicated to discovering, developing and commercializing prescription pharmaceutical products in disease areas with significant commercial potential and unmet medical needs. Inspire employs a U.S. sales force for the promotion of AzaSite(TM) (azithromycin ophthalmic solution) 1% for bacterial conjunctivitis, Elestat(R) (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis(R) (cyclosporine ophthalmic emulsion) 0.05% for dry eye. Inspire is focused on the therapeutic areas of ophthalmology and respiratory/allergy, and is developing products for dry eye, cystic fibrosis, allergic rhinitis and glaucoma. Elestat and Restasis are trademarks owned by Allergan, Inc. AzaSite is a trademark owned by InSite Vision Incorporated. For more information, visit www.inspirepharm.com.
Source: Inspire Pharmaceuticals, Inc.
----------------------------------------------
Inspire Pharmaceuticals
Inc.
Investor Contact:
Jenny Kobin
919-941-9777
Extension 219
VP
Investor Relations and Corporate Communications
or
Media Contact:
BMC Communications
Dan Budwick
212-477-9007
Extension 14
